Published online Mar 16, 2021. doi: 10.12998/wjcc.v9.i8.1968
Peer-review started: November 5, 2020
First decision: December 24, 2020
Revised: December 30, 2020
Accepted: January 22, 2021
Article in press: January 22, 2021
Published online: March 16, 2021
Processing time: 120 Days and 3.6 Hours
Acquired pure red cell aplasia (aPRCA) related to human parvovirus B19 (HPV B19) is rarely reported in simultaneous pancreas-kidney transplantation (SPKT) recipients; there has yet to be a case report of early postoperative infection. In this current study, we report the case of a Chinese patient who experienced the disease in the early postoperative period.
A 63-year-old man, with type 2 diabetes and end-stage renal disease, received a brain dead donor-derived SPKT. Immunosuppression treatment consisted of tacrolimus, prednisone, enteric-coated mycophenolate sodium (EC-MPS), and thymoglobulin combined with methylprednisolone as induction. The hemoglobin (Hb) level declined due to melena at postoperative day (POD) 3, erythropoietin-resistant anemia persisted, and reticulocytopenia was diagnosed at POD 20. The bone marrow aspirate showed decreased erythropoiesis and the presence of giant pronormoblasts at POD 43. Metagenomic next-generation sequencing (mNGS) of a blood sample identified HPV B19 infection at POD 66. EC-MPS was withdrawn; three cycles of intravenous immunoglobulin (IVIG) infusion therapy were administered; and tacrolimus was switched to cyclosporine. The HPV B19-associated aPRCA resolved completely and did not relapse within the 1-year follow-up period. The diminution in mNGS reads was correlated with Hb and reticulocyte count improvements.
HPV B19-associated aPRCA can occur at an early period after SPKT. An effective therapy regimen includes IVIG infusion and adjustment of the immuno-suppressive regimen. Moreover, mNGS can be used for the diagnosis and to reflect disease progression.
Core Tip: This study presents a patient who developed human parvovirus (HPV) B19-associated acquired pure red cell aplasia (aPRCA) in the early postoperative period following simultaneous pancreas-kidney transplantation. Metagenomic next-generation sequencing (mNGS) was used to diagnose HPV B19 infection and the diminution in mNGS reads was correlated with hemoglobin and reticulocyte count improvements. Effective therapy included intravenous immunoglobulin infusion and adjustment of the immunosuppressive regimen. HPV B19-associated aPRCA should be considered when a patient experiences erythropoietin-resistant anemia and reticulocytopenia in the early postoperative period. Moreover, mNGS could be used for diagnosis and to reflect disease progression.